Saved local watchlist · Deprioritization mentions · sorted by registry update date
Candidate queue
877 active trial–asset records · showing latest 25 · no composite ranking
An ingestion window is pending. Refresh resumes the next page.
| Asset / trial | Sponsor / phase | Status / stopping reason | Independent scores | Source |
|---|---|---|---|---|
| CemiplimabNCT07414992 | Memorial Sloan Kettering Cancer CenterPHASE2 | WITHDRAWN The sponsor is no longer supporting the trial because they are no longer interested in studying the drug in the target patient population. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-03 |
| Dual X-ray AbsorptiometryNCT06671912 | Alliance for Clinical Trials in OncologyPHASE3 | SUSPENDED Amending protocol to increase sample size | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2026-09-02 |
| TamoxifenNCT06671912 | Alliance for Clinical Trials in OncologyPHASE3 | SUSPENDED Amending protocol to increase sample size | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2026-09-02 |
| ExemestaneNCT06671912 | Alliance for Clinical Trials in OncologyPHASE3 | SUSPENDED Amending protocol to increase sample size | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2026-09-02 |
| LetrozoleNCT06671912 | Alliance for Clinical Trials in OncologyPHASE3 | SUSPENDED Amending protocol to increase sample size | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2026-09-02 |
| AnastrozoleNCT06671912 | Alliance for Clinical Trials in OncologyPHASE3 | SUSPENDED Amending protocol to increase sample size | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2026-09-02 |
| GS-2872NCT06071767 | National Institute of Allergy and Infectious Diseases (NIAID)PHASE1, PHASE2 | SUSPENDED Temporarily Closed (Paused) to Accrual and Study Agents/Products | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-02 |
| GS-5423NCT06071767 | National Institute of Allergy and Infectious Diseases (NIAID)PHASE1, PHASE2 | SUSPENDED Temporarily Closed (Paused) to Accrual and Study Agents/Products | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-02 |
| Vesatolimod (VES)NCT06071767 | National Institute of Allergy and Infectious Diseases (NIAID)PHASE1, PHASE2 | SUSPENDED Temporarily Closed (Paused) to Accrual and Study Agents/Products | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-02 |
| MVA.tHIVconsv4NCT06071767 | National Institute of Allergy and Infectious Diseases (NIAID)PHASE1, PHASE2 | SUSPENDED Temporarily Closed (Paused) to Accrual and Study Agents/Products | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-02 |
| MVA.tHIVconsv3NCT06071767 | National Institute of Allergy and Infectious Diseases (NIAID)PHASE1, PHASE2 | SUSPENDED Temporarily Closed (Paused) to Accrual and Study Agents/Products | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-02 |
| ChAdOx1.HIVconsv62NCT06071767 | National Institute of Allergy and Infectious Diseases (NIAID)PHASE1, PHASE2 | SUSPENDED Temporarily Closed (Paused) to Accrual and Study Agents/Products | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-02 |
| ChAdOx1.tHIVconsv1NCT06071767 | National Institute of Allergy and Infectious Diseases (NIAID)PHASE1, PHASE2 | SUSPENDED Temporarily Closed (Paused) to Accrual and Study Agents/Products | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-02 |
| IX001 TCR-T cellsNCT06487377 | Shanghai Pudong HospitalPHASE1 | WITHDRAWN Study was stopped Sponsor discretion. No patients were dosed. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-02 |
| PegcetacoplanNCT07020832 | Apellis Pharmaceuticals, Inc.PHASE3 | WITHDRAWN The study was terminated following portfolio reprioritization and reallocation of resources to other development programs. The decision was not driven by safety or efficacy concerns arising from this trial. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihood75 Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-02 |
| DocetaxelNCT05378763 | Spectrum Pharmaceuticals, IncPHASE3 | SUSPENDED The study has not enrolled any patients. The study design is under discussion and will likely be redesigned in consultation with the FDA. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2026-09-01 |
| PoziotinibNCT05378763 | Spectrum Pharmaceuticals, IncPHASE3 | SUSPENDED The study has not enrolled any patients. The study design is under discussion and will likely be redesigned in consultation with the FDA. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2026-09-01 |
| PrednisoneNCT05279300 | CStone PharmaceuticalsPHASE1 | SUSPENDED The sponsor is temporarily pausing the trial to evaluate existing clinical data for long-term benefit-risk and optimize doses and dosing schedule. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2026-09-01 |
| VincristineNCT05279300 | CStone PharmaceuticalsPHASE1 | SUSPENDED The sponsor is temporarily pausing the trial to evaluate existing clinical data for long-term benefit-risk and optimize doses and dosing schedule. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2026-09-01 |
| DoxorubicinNCT05279300 | CStone PharmaceuticalsPHASE1 | SUSPENDED The sponsor is temporarily pausing the trial to evaluate existing clinical data for long-term benefit-risk and optimize doses and dosing schedule. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2026-09-01 |
| CyclophosphamideNCT05279300 | CStone PharmaceuticalsPHASE1 | SUSPENDED The sponsor is temporarily pausing the trial to evaluate existing clinical data for long-term benefit-risk and optimize doses and dosing schedule. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2026-09-01 |
| LenalidomideNCT05279300 | CStone PharmaceuticalsPHASE1 | SUSPENDED The sponsor is temporarily pausing the trial to evaluate existing clinical data for long-term benefit-risk and optimize doses and dosing schedule. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2026-09-01 |
| OxaliplatinNCT05279300 | CStone PharmaceuticalsPHASE1 | SUSPENDED The sponsor is temporarily pausing the trial to evaluate existing clinical data for long-term benefit-risk and optimize doses and dosing schedule. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2026-09-01 |
| GemcitabineNCT05279300 | CStone PharmaceuticalsPHASE1 | SUSPENDED The sponsor is temporarily pausing the trial to evaluate existing clinical data for long-term benefit-risk and optimize doses and dosing schedule. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2026-09-01 |
| RituximabNCT05279300 | CStone PharmaceuticalsPHASE1 | SUSPENDED The sponsor is temporarily pausing the trial to evaluate existing clinical data for long-term benefit-risk and optimize doses and dosing schedule. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2026-09-01 |
Recent ingestion runs
| Source | Studies seen | Candidate writes | Status / finished |
|---|---|---|---|
| pubmed | 240 | 100 | finished2026-09-21T03:58:28.397783+00:00 |
| pubmed | 0 | 0 | failed2026-09-21T03:48:59.232056+00:00 |
| sec | 0 | 0 | finished2026-09-21T03:48:59.212906+00:00 |
| ClinicalTrials.gov | 300 | 258 | partial2026-09-21T03:48:59.189357+00:00 |
| ClinicalTrials.gov | 300 | 305 | Legacy run2026-09-21T03:45:47.341408+00:00 |
| ClinicalTrials.gov | 300 | 348 | Legacy run2026-09-21T03:38:48.082427+00:00 |